MEXICO Trends and Developments Contributed by: Carlos de la Garza, Raúl Acosta and Enrique Tamez, De la Garza & Acosta Abogados, S.C.
This situation affects not only disputes between insureds and insurers but also administrative con- flicts involving sanctions, product authorisations or regulatory oversight. In Mexico, a substantial number of disputes of any nature ultimately reach resolution through amparo proceedings, where magistrates are now popularly elected and many of them have been promoted or supported by the dominant political par- ty. Even the Supreme Court of Justice of the Nation has been impacted by this process, now being com- posed of nine justices elected through open selection mechanisms that, in practice, were influenced by the ruling political force. Although most reinsurance-related disputes in Mexico are resolved through commercial arbitration before private arbitrators, this sector will not remain immune to the effects of the current judicial environment. The enforcement of arbitral awards derived from such pro- ceedings ultimately falls within the jurisdiction of the federal courts, which are now composed of judges and magistrates elected through popular vote. As a result, the neutrality and technical consistency tradi- tionally associated with arbitral enforcement may be subject to greater uncertainty, particularly in cases involving complex coverage or reinsurance structures. Pressures in the health insurance sector Private health insurance (commonly referred to in Mexico as major medical expense insurance) has become one of the most complex and sensitive seg- ments of the Mexican insurance market, not due to inherent deficiencies in the insurance product itself, but because of the structural distortions that persist within the private healthcare delivery system. In recent years, loss ratios have increased steadily, driven pri- marily by the rapid growth in hospital costs, the con- stant evolution of highly specialised treatments and greater use of healthcare services by the insured population. A substantial part of this pressure stems from the pric- ing and adjustment mechanisms employed by hos- pitals, medical specialists and suppliers of medical inputs. The absence of standardised reference mech- anisms, together with fragmented negotiations over physicians’ fees, hospital tariffs and treatment costs, has led to recurrent and unpredictable increases in
the cost of care. These increases occur independently of the technical loss ratio of the insurance itself and largely escape any direct control by insurers. This environment has caused medical costs to rise at a pace exceeding general inflation and well beyond the absorption capacity of the insurance system. In this context, insurers operate as mere financial con- duits, obliged to transfer externally determined prices within a pre-agreed contractual framework. The result- ing economic pressure therefore does not stem from discretionary coverage decisions, but from the pricing dynamics imposed by healthcare providers. As a consequence of this structure, adjustments to premiums, deductibles and contractual terms have become inevitable to preserve the product’s viability. However, from the policyholder’s perspective, such adjustments are often perceived as unjustified restric- tions or as a progressive reduction in the scope of coverage. This perception has increased the number of complaints, even though the root cause lies in the escalation of medical costs rather than in the execu- tion of the insurance contract itself. The most frequent disputes in this segment have focused on issues such as the determination of pre- existing conditions, the application of waiting periods and the interpretation of limits or sub-limits of cover- age, particularly for high-cost treatments. These dis- putes, far from reflecting systemic failures by insurers, highlight the difficulty of reconciling broad expecta- tions of coverage with a private medical system char- acterised by rising and poorly standardised prices. The increase in the cost of specialised medicines and next-generation pharmaceutical treatments has further deepened these tensions. In many cases, the prices of certain drugs and therapies quickly exceed the original actuarial projections, creating friction dur- ing the claims process. Once again, these increases respond to market policies of healthcare providers rather than to decisions made by insurers themselves. This context has led to a significant rise in claims before administrative authorities and to greater judi- cialisation of disputes related to health insurance. As a result, this line of business has become one of the
351 CHAMBERS.COM
Powered by FlippingBook